Skip to main navigation Skip to search Skip to main content

3,4-Dihydroxyphenylacetaldehyde-induced protein modifications and their mitigation by N-Acetylcysteine

  • Yunden Jinsmaa*
  • , Yehonatan Sharabi
  • , Patti Sullivan
  • , Risa Isonaka
  • , David S. Goldstein
  • *Corresponding author for this work
  • National Institutes of Health

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

The catecholaldehyde hypothesis posits that 3,4-dihydroxyphe-nylacetaldehyde (DOPAL), an obligate intermediary metabolite of dopamine, is an autotoxin that challenges neuronal homeostasis in catecholaminergic neurons. DOPAL toxicity may involve protein modifications, such as oligomerization of a-synuclein (AS). Potential interactions between DOPAL and other proteins related to catecholaminergic neurodegeneration, however, have not been systemically explored. This study examined DOPAL-induced protein-quinone adduct formation (“quinonization”) and protein oligomerization, ubiquitination, and aggregation in cultured MO3.13 human oligodendrocytes and PC12 rat pheochromocytoma cells and in test tube experiments. Using near-infrared fluorescence spectroscopy, we detected spontaneous DOPAL oxidation to DOPAL-quinone, DOPAL-induced quinonization of intracellular proteins in both cell lines, and DOPAL-induced quinonization of several proteins related to catecholaminergic neurodegeneration, including AS, the type 2 vesicular monoamine transporter, glucocerebrosidase, ubiquitin, and L-aromatic-amino-acid decarboxylase (LAAAD). DOPAL also oligomerized AS, ubiquitin, and LAAAD; inactivated LAAAD (IC 50 54 mM); evoked substantial intracellular protein ubiquitination; and aggregated intracellular AS. Remarkably, N-acetylcysteine, which decreases DOPAL-quinone formation, attenuated or prevented all of these protein modifications and functional changes. The results fit with the proposal that treatments based on decreasing the formation and oxidation of DOPAL may slow or prevent catecholaminergic neurodegeneration.

Original languageEnglish
Pages (from-to)113-124
Number of pages12
JournalJournal of Pharmacology and Experimental Therapeutics
Volume366
Issue number1
DOIs
StatePublished - Jul 2018

Funding

FundersFunder number
National Institute of Neurological Disorders and StrokeZIANS003125

    Fingerprint

    Dive into the research topics of '3,4-Dihydroxyphenylacetaldehyde-induced protein modifications and their mitigation by N-Acetylcysteine'. Together they form a unique fingerprint.

    Cite this